Table 2.
Tumor cell line |
Oil conc. µg/ml | % cell survival ±SEM | ||
Leaf oil (100µl/disc) |
Berry oil (100µl/disc) |
Cisplatin | ||
bU251 | 0 | 100 ± 0.06 | 100 ± 0.10 | 100 ± 0.07 |
1 | 13.5 ± 0.03 | 17.2 ± 0.07 | 60.9 ± 0.07 | |
2.5 | 14.0 ± 0.03 | 7.7 ± 0.06 | 56.4 ± 0.05 | |
5 | 3.3 ± 0.01 | 5.2 ± 0.07 | 55.5± 0.07 | |
10 | 7.5 ± 0.04 | 7.0 ± 0.04 | 49.4± 0.05 | |
cH460 | 0 | 100 ± 0.08 | 100 ± 0.08 | 100 ± 0.07 |
1 | 34.0 ± 0.05 | 23.5 ± 0.04 | 79.6 ± 0.02 | |
2.5 | 21.6 ± 0.06 | 27.1 ± 0.03 | 66.5 ± 0.05 | |
5 | 16.7 ± 0.02 | 19.9 ± 0.06 | 48.8 ± 0.03 | |
10 | 9.8 ± 0.03 | 18.0 ± 0.02 | 40.1 ± 0.0 | |
dHepg2 | 0 | 100 ± 0.09 | 100 ± 0.07 | 100 ± 0.10 |
1 | 44.2 ± 0.06 | 24.7 ± 0.0 | 60.1 ± 0.04 | |
2.5 | 32.8 ± 0.05 | 29.9 ± 0.03 | 59.3 ± 0.06 | |
5 | 22.0 ± 1.0 | 27.0 ± 0.05 | 52.4 ± 0.04 | |
10 | 29.6 ± 0.0 | 37.9 ± 0.09 | 51.8 ± 0.05 | |
eMCF7 | 0 | 100 ± 0.10 | 100 ± 0.10 | |
1 | 52.1 ± 0.04 | 34.6 ± 0.04 | ||
2.5 | 42.5 ± 0.07 | 33.8 ± 0.03 | NT | |
5 | 37.1 ± 0.06 | 33.5 ± 0.04 | ||
10 | 30.7 ± 0.01 | 20.6 ± 0.01 | ||
fHela | 0 | 100 ± 0.09 | 100 ± 0.08 | 100 ± 0.08 |
1 | 73.4 ± 0.08 | 83.5 ± 0.07 | 90.3 ± 0.06 | |
2.5 | 70.9 ± 0.04 | 70.6 ± 0.08 | 42.4 ± 0.02 | |
5 | 51.5 ± 0.02 | 48.7 ± 0.06 | 17.0 ± 0.04 | |
10 | 11.0 ± 0.0 | 38.2 ± 0.02 | 5.9 ± 0.02 |
aOil concentration (µg/ml) required to reduce cell survival by 50%, bbrain tumor cell line, clung carcinoma cell line, dliver carcinoma cell line, ebreast carcinoma cell line, fcervix carcinoma cell line. NT: not testes.
Cisplatin: standard antitumor drug.